- Home
- QNCX vs ZURA Comparison
QNCX vs ZURA Comparison
Compare QNCX & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- ZURA
- Stock Information
- Founded
- QNCX 2012
- ZURA 2022
- Country
- QNCX United States
- ZURA United States
- Employees
- QNCX N/A
- ZURA N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QNCX Health Care
- ZURA Health Care
- Exchange
- QNCX Nasdaq
- ZURA Nasdaq
- Market Cap
- QNCX 85.9M
- ZURA 69.9M
- IPO Year
- QNCX 2019
- ZURA N/A
- Fundamental
- Price
- QNCX $1.60
- ZURA $1.92
- Analyst Decision
- QNCX Strong Buy
- ZURA Buy
- Analyst Count
- QNCX 6
- ZURA 10
- Target Price
- QNCX $8.00
- ZURA $12.67
- AVG Volume (30 Days)
- QNCX 124.9K
- ZURA 334.1K
- Earning Date
- QNCX 11-12-2025
- ZURA 11-06-2025
- Dividend Yield
- QNCX N/A
- ZURA N/A
- EPS Growth
- QNCX N/A
- ZURA N/A
- EPS
- QNCX N/A
- ZURA N/A
- Revenue
- QNCX N/A
- ZURA N/A
- Revenue This Year
- QNCX N/A
- ZURA N/A
- Revenue Next Year
- QNCX N/A
- ZURA N/A
- P/E Ratio
- QNCX N/A
- ZURA N/A
- Revenue Growth
- QNCX N/A
- ZURA N/A
- 52 Week Low
- QNCX $0.69
- ZURA $0.97
- 52 Week High
- QNCX $2.45
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- QNCX 47.89
- ZURA 50.23
- Support Level
- QNCX $1.56
- ZURA $1.97
- Resistance Level
- QNCX $1.65
- ZURA $2.19
- Average True Range (ATR)
- QNCX 0.07
- ZURA 0.15
- MACD
- QNCX 0.00
- ZURA -0.03
- Stochastic Oscillator
- QNCX 64.65
- ZURA 10.00
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.